<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055847</url>
  </required_header>
  <id_info>
    <org_study_id>CP-AI-003</org_study_id>
    <nct_id>NCT01055847</nct_id>
  </id_info>
  <brief_title>Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis &amp; P. Aeruginosa Infection</brief_title>
  <official_title>A Blinded, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam for Inhalation (AI) in Cystic Fibrosis Patient With Lung Disease Due to P. Aeruginosa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salus Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two
      dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is multicenter placebo-controlled study evaluating the safety and efficacy of a 14-day
      treatment of AI at two dosage levels as compared to placebo, given twice daily, in CF
      patients with P. aeruginosa lung infection, delivered by the eFlow investigational nebulizer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 from Baseline to Day 14</measure>
    <time_frame>14 Days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>CF</condition>
  <condition>Lung Infection</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <arm_group>
    <arm_group_label>AI 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aztreonam for Inhalation 75 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AI 225 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aztreonam for Inhalation 225 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam for Inhalation (AI)</intervention_name>
    <description>Aztreonam for Inhalation</description>
    <arm_group_label>AI 75 mg</arm_group_label>
    <arm_group_label>AI 225 mg</arm_group_label>
    <other_name>AI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to the performance of any study related procedures.

          -  13 years of age and above.

          -  Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test
             (QPIT) or homozygosity for ΔF508 genetic mutation or heterozygosity for two well
             characterized mutations.

          -  Ability to perform pulmonary function tests.

          -  FEV1 ≥ 40% predicted at Visit 1 (Screening).

          -  SaO2 ≥ 90% at Visit 1 (Screening).

          -  P. aeruginosa present in sputum at Visit 1 (Screening).

          -  Ability to expectorate sputum on a daily basis.

        Exclusion Criteria:

          -  Administration of any antibiotic with antipseudomonal activity by any route within 56
             days prior to Visit 1 (Screening).

          -  Administration of any investigational drug or device within 28 days of Visit 1
             (Screening) and within 6 half-lives of the investigational drug.

          -  Oral corticosteroids in doses exceeding 10 mg per day or 20 mg every other day.

          -  History of sputum culture or throat swab culture yielding B. cepacia in the previous
             two years.

          -  Current daily continuous oxygen supplementation or requirement for more than 2 L/min
             at night.

          -  Known local or systemic hypersensitivity to monobactam antibiotics.

          -  Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid
             medications within 7 days prior to Visit 1 (Screening).

          -  Changes in physiotherapy technique or schedule within 7 days prior to Visit 1
             (Screening).

          -  History of lung transplantation.

          -  A chest radiograph at Visit 1 (Screening) or within the previous 90 days of Screening,
             with abnormalities indicating a significant acute finding (eg, lobar infiltrate and
             atelectasis, pneumothorax, or pleural effusion).

          -  Abnormal renal or hepatic function or serum chemistry at Visit 1 (Screening):

               -  AST, ALT &gt; 2.5 times upper limit of normal range.

               -  Creatinine &gt; 1.5 times upper limit of normal range.

          -  Positive pregnancy test. All women of childbearing potential will be tested.

          -  Female of childbearing potential who is lactating or is not practicing acceptable
             method of birth control (eg, hormonal or barrier methods, or IUD).

          -  Findings at Visit 1 (Screening) that, in the investigator's opinion, would compromise
             the safety of the patient or the quality of the study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald L Gibson, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital and Regional Medica Center, Seattle, WA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Retsch-Bogart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina Hospitals, Chapel Hill, NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>January 25, 2010</last_update_submitted>
  <last_update_submitted_qc>January 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>A. Bruce Montgomery, Sr. VP Gilead Sciences</name_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>CF</keyword>
  <keyword>aztreonam</keyword>
  <keyword>lung infection</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aztreonam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

